Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?

Future Oncology

Volumn 7, Issue 7, 2011, Pages 807-810

  Kaumaya, Pravin Tp ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

angiogenesis; cancer vaccine; HER 2; peptide therapy; peptidomimetics; VEGF

Indexed keywords

ANTIBODY; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; LAPATINIB; PEPTIDE; PEPTIDE EPITOPE; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT VASCULOTROPIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

AUTOIMMUNE DISEASE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARDIOTOXICITY; CELL VIABILITY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CANCER VACCINES; EPITOPES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; VACCINES, SUBUNIT;

EID: 79960149835     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.60     Document Type: Editorial

References (19)

1. Houck KA, Ferrara N, Winer J et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806-1814 (1991)
2. Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117-124 (2003) (Pubitemid 37433402)
3. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005) (Pubitemid 40637826)
4. Hudziak RM, Lewis GD, Winget M et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172 (1989) (Pubitemid 19071685)
5. Shepard HM, Lewis GD, Sarup JC et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-127 (1991)
6. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 92(Suppl. 1), S6-S13 (2005) (Pubitemid 40897411)
7. Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39, 1095-1100 (2002) (Pubitemid 34620130)
8. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 42, 3127-3139 (2006) (Pubitemid 44869016)
9. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park) 20, 21-28 (2006)
10. Dakappagari NK, Douglas DB, Triozzi PL et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60, 3782-3789 (2000) (Pubitemid 32204569)
11. Dakappagari NK, Pyles J, Parihar R et al. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J. Immunol. 170, 4242-4253 (2003) (Pubitemid 36428191)
12. Kaumaya PT, Foy KC, Garrett J et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol. 27, 5270-5277 (2009)
13. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 (2003) (Pubitemid 36227628)
14. Garrett TP, McKern NM, Lou M et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003) (Pubitemid 36293841)
15. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328 (2004) (Pubitemid 38482068)
16. Garrett JT, Rawale S, Allen SD et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J. Immunol. 178, 7120-7131 (2007) (Pubitemid 46847438)
17. Allen SD, Garrett JT, Rawale SV et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J. Immunol. 179, 472-482 (2007) (Pubitemid 46986564)
18. Vicari D, Foy KC, Liotta EM et al. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J. Biol. Chem. 286, 13612-13625 (2011)
19. Foy KC, Liu Z, Phillips G et al. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J. Biol. Chem. 286, 13626-13637 (2011